RxDoctor Payments Data

Ralf Vander Sluis, MD

Neurology · Somers Point, NJNPI 1568493088

Payments from drug & device makers

$8,036in general payments, 2019–2025

Across 448 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Bristol Myers Squibb$610
  • AbbVie$547
  • Supernus Pharmaceuticals, Inc.$497
  • Novartis$462
  • Eisai Inc.$423
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$8,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,036 in reported general payments places this provider in the 65th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$186,490
Medicare patients
718
Services billed
2,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4621$421,976
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$248,322
MayzentSiponimod12$107,387
QuliptaAtogepant44$64,835
UbrelvyUbrogepant53$60,674
Nurtec OdtRimegepant Sulfate26$33,365
Emgality PenGalcanezumab-Gnlm21$32,778
Aimovig AutoinjectorErenumab-Aooe12$19,708
Lacosamide31$10,630
Memantine Hcl214$9,587
Gabapentin278$6,038
Levetiracetam140$5,928
Galantamine Hbr45$5,109
Donepezil Hcl391$4,872
Carbidopa-LevodopaCarbidopa/Levodopa140$4,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$547$125,50997 claims
NovartisMayzent$462$107,38712 claims
PfizerNurtec Odt$170$33,36526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 521 neurology providers in New Jersey.

Other neurology in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →